BioWorld2d
Pfizer’s PD-1 inhibitor hits endpoint in BCG-naïve bladder cancer
Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...
Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial
Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer.
Pfizer's bladder cancer therapy meets main goal in late-stage study
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...
BioSpace2d
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Pfizer's Sasanlimab Hits Late-Stage Study Primary Endpoint for Bladder Cancer
Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...